NextCell publishes opinion piece with ISCT

October 11, 2022

NextCell Pharma AB (”NextCell” or ”Company”)published an opinion piece on particulates in cell and gene therapy products with the International Society for Cell and Gene Therapy’s Process Development, Manufacturing and Analytics Committee last week in the journal Cytotherapy.

NextCell Pharma AB is a cell therapy company working in the development and commercialization of the mesenchymal stromal cell therapy product, ProTrans. This product, with its proprietary platform technology, is in clinical development for the treatment of autoimmune conditions, such as type I diabetes and inflammatory conditions such as viral pneumonia.

 

NextCell’s CEO, Mathias Svahn and CSO, Lindsay Davies are active members of the International Society for Cell and Gene Therapy (ISCT), the leading global society for the development and commercialization of advanced therapeutics. Dr Davies is a member of both the ISCT Commercialization Committee and Process Development, Manufacturing and Analytics Committee and an ISCT mentor for early stage professionals entering the cell therapy space. The Process Development, Manufacturing and Analytics working group brings together scientists and cell and gene therapy companies, in all stages of commercial development, to discuss current issues in the advanced therapy arena and lead forward thinking in these novel and evolving areas of clinical development.

 

“It has been great to work with such a diverse and knowledgeable group of scientists and business developers from across the globe to discuss ways of addressing and supporting cell and gene therapy development. The NextCell team is committed to actively participating in advancing knowledge and understanding, promoting regulatory change and thereby ensure wider accessibility of safe cell and gene therapies for patients”, says Dr Davies.

 

Last week Lindsay Davies and the Process Development, Manufacturing and Analytics Committee published an opinion piece in the journal Cytotherapy. The piece entitled, “Particulates are everywhere, but are they harmful in cell and gene therapies?” addresses the potential issue of evaluating particulate matter in cell and gene therapy products, and the need for regulations to differentiate this distinct class of drugs from other, more traditional pharmaceutical products.

 

The published article can be accessed, for free, at https://authors.elsevier.com/a/1fpxZ5DBIBTE%7EZ until November
16, 2022.

For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
E-mail: info@nextcellpharma.com
Homepage: www.nextcellpharma.com
 
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

 

About NextCell Pharma AB:
NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

Download attachmentRead full press release on Cision (external link)
2025-03-28
NextCell’s CSO Appointed to the Board of ATMP Sweden
NextCell Pharma AB ("NextCell") proudly announces that the company’s Chief Scientific Officer (CSO), Dr. Lindsay Davies, has been appointed to the board of ATMP Sweden. This further reinforces both her role and NextCell’s position as a key player in the development of advanced therapies, both nationally and internationally.
Read moreRead more
2025-03-19
Recognition for NextCell’s CSO from the International Society of Cell and Gene Therapy
NextCell Pharma AB ("NextCell" or "the Company") announces that its CSO, Lindsay Davies, has been asked to lead the inaugural International Society of Cell and Gene Therapy (ISCT) industry committee for Europe and has been nominated as Vice President Elect in the 2025 ISCT elections.
Read moreRead more
2025-03-13
Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv
NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient in the older age cohort (12–21 years) of the clinical Phase II study, ProTrans-Young, has now completed their 12-month follow-up. The collected data is currently being compiled, and an administrative subgroup analysis is planned to be presented at the IDF World Diabetes Congress in Bangkok from April 7–10.
Read moreRead more
2025-02-19
All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study
NextCell Pharma AB ("NextCell") announced today that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, have been treated. The study is being conducted at Örebro University Hospital and includes a total of nine patients, with three patients in each dose group.  
Read moreRead more
2025-01-30
NextCell Pharma publish Interim Report 1 2024/2025
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Read moreRead more
2024-12-17
Long-term Effects with Repeated ProTrans Treatment After 6 Years
NextCell Pharma AB reports new results from the ProTrans-Repeat study, where type 1 diabetes patients have been followed for 5 years after receiving two doses of the stromal cell product ProTrans, in total 6 years after the first infusion. The results show that two out of three patients in the high-dose group increased their insulin production by 23% and 34% respectively.
Read moreRead more
2024-12-05
NextCell Pharma changes Certified Adviser to Redeye AB
NextCell Pharma has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on January 1, 2025.
Read moreRead more
2024-11-25
QVance’s Partnerships Driving Innovation in Advanced Therapies
NextCell Pharma AB*, parent company of QVance, proudly supports QVance’s newly announced partnership with Royale International. This collaboration, which combines Royale International’s global expertise in logistics with QVance’s innovative quality control solutions, strengthens the supply chain for cell and gene therapies across Europe.
Read moreRead more